Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares traded up 7.4% on Monday . The company traded as high as $13.40 and last traded at $13.54. 127,068 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 234,912 shares. The stock had previously closed at $12.60.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the company. Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 15th. BTIG Research assumed coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating on the stock. Finally, Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $40.38.
View Our Latest Analysis on ORKA
Oruka Therapeutics Stock Performance
The firm has a market cap of $497.58 million, a P/E ratio of -2.95 and a beta of -0.34. The company has a 50 day moving average of $11.22 and a 200 day moving average of $11.98.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.
Institutional Investors Weigh In On Oruka Therapeutics
Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics in the 4th quarter worth approximately $303,000. Vanguard Group Inc. lifted its holdings in Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after purchasing an additional 1,572,853 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics in the 4th quarter worth approximately $54,000. Wellington Management Group LLP lifted its holdings in Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after purchasing an additional 12,952 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Oruka Therapeutics by 2,348.6% in the 4th quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock worth $6,643,000 after purchasing an additional 328,434 shares during the last quarter. Institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.